Edema Clinical Trials Market Report 2026

Edema Clinical Trials Market Overview

• Edema Clinical Trials market size has reached to $1.23 billion in 2025 • Expected to grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Rising Lifestyle-Related Diseases Driving The Market Growth Due To Unhealthy Lifestyles And Related Health Complications • Market Trend: Advancements In Sustained-Release Eye Implants For Chronic Edema • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Edema Clinical Trials Market?

Edema clinical trials refer to clinical studies conducted to evaluate the safety, efficacy, and potential treatments for edema, the abnormal accumulation of fluid in the body’s tissues. These trials may investigate drugs, medical devices, or therapeutic interventions aimed at reducing swelling, improving fluid balance, or addressing underlying causes such as heart, kidney, or liver disorders. The main phase types of edema clinical trials are Phase I, Phase II, Phase III, and Phase IV. Phase I refers to the first stage of clinical trials, focusing on assessing the safety, tolerability, and optimal dosage of a new therapy in a small group of participants. The trials address various types, including peripheral edema, pulmonary edema, cerebral edema, and nephrotic syndrome edema, they are conducted using study designs that include interventional, observational, and expanded access. Participants in these trials span pediatrics, adults, and geriatrics, and the main end users include pharmaceutical companies, research institutions, contract research organizations (CROs), and academic research centers.

What Is The Edema Clinical Trials Market Growth Forecast?

The edema clinical trials market size is expected to see strong growth in the next few years. It will grow to $1.85 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for targeted edema therapies, rising use of decentralized clinical trial models, expansion of precision medicine approaches, growing integration of digital data capture tools, increased regulatory support for innovative trial designs. Major trends in the forecast period include increasing use of AI-assisted patient recruitment, rising adoption of adaptive trial designs, growing focus on biomarker-based endpoints, expansion of multi-center global trials, enhanced emphasis on real-world evidence integration.

Global Edema Clinical Trials Market Segmentation

1) By Phase: Phase I, Phase II, Phase III, Phase IV 2) By Type: Peripheral Edema, Pulmonary Edema, Cerebral Edema, Nephrotic Syndrome Edema 3) By Study Design: Interventional, Observational, Expanded Access 4) By Participant: Pediatrics, Adults, Geriatrics 5) By End User: Pharmaceutical Companies, Research Institutions, Contract Research Organizations (CROs), Academic Research Centers Subsegments: 1) By Phase I: Single Ascending Dose, Multiple Ascending Dose 2) By Phase II: Proof of Concept, Phase IIb Dose Optimization 3) By Phase III: Pivotal Efficacy Trials, Comparative Trials 4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies

What Is The Driver Of The Edema Clinical Trials Market?

The increasing incidence of lifestyle-related diseases is expected to propel the growth of the edema clinical trials market going forward. Lifestyle-related diseases are illnesses that arise from daily behaviors and choices, including sedentary lifestyle, unhealthy eating, and substance use. Lifestyle-related diseases are increasing due to unhealthy dietary habits, as the widespread consumption of processed and high-calorie foods contributes to obesity, diabetes, and cardiovascular problems. Edema clinical trials support lifestyle-related diseases by developing and assessing treatments that address fluid buildup linked to obesity, diabetes, and cardiovascular conditions. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the increasing incidence of lifestyle-related diseases is driving the growth of the edema clinical trials industry.

Key Players In The Global Edema Clinical Trials Market

Major companies operating in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG

Global Edema Clinical Trials Market Trends and Insights

Major companies operating in the edema clinical trials market are focusing on developing innovative solutions such as refillable ocular implants to improve treatment efficacy and patient compliance in managing chronic edema-related eye conditions. A refillable ocular implant refers to a medical device implanted in the eye that can continuously deliver medication over an extended period and allows periodic refilling of the drug without needing to remove or replace the implant, ensuring sustained treatment for chronic eye conditions like macular edema. For instance, in February 2025, Roche Holding AG, a Switzerland-based pharmaceutical company, received approval from the FDA for Susvimo as the first and only continuous delivery treatment for diabetic macular edema (DME) and diabetic retinopathy (DR), both major causes of diabetes-related blindness, offering an alternative to frequent eye injections with significantly fewer annual treatments. This innovative approval marks a significant advancement in ophthalmic care, as Susvimo’s implantable delivery system helps improve patient compliance and reduces the treatment burden, potentially enhancing long-term outcomes for individuals living with these chronic eye conditions.

What Are Latest Mergers And Acquisitions In The Edema Clinical Trials Market?

In September 2025, Alcon Inc., a Switzerland-based eye care device company, acquired LumiThera Inc. for an undisclosed amount. With this acquisition, Alcon aims to expand access to LumiThera’s Valeda photobiomodulation device for early and intermediate dry AMD, broadening its retinal treatment portfolio into clinic-based, noninvasive therapies to help millions of patients gain vision. LumiThera Inc. is a US-based ophthalmic medical device company that offers edema clinical trials.

Regional Outlook

North America was the largest region in the edema clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Edema Clinical Trials Market?

The edema clinical trials market includes revenues earned by entities by providing services such as patient recruitment and screening, safety and adverse event reporting, and regulatory compliance support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Edema Clinical Trials Market Report 2026?

The edema clinical trials market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the edema clinical trials industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.